Search

everythinglearnresearchcommunity

for

Search:↓

Rezpegaldesleukin shows promise for treating severe alopecia areata.

Mogamulizumab can cause hair loss and skin rashes.

Azathioprine can help with relapses and disability in NMOSD but has more side effects and needs more research.

Budesonide is not effective for maintaining remission in Crohn's disease beyond three months.

The choice between belimumab and anifrolumab for treating lupus depends on the patient's specific symptoms.

Pimecrolimus boosts melanin production and movement of skin pigment cells.

The choice between belimumab and anifrolumab depends on the specific symptoms of the patient's lupus.

Mogamulizumab treatment in Sézary syndrome may cause skin issues and hair loss but can lead to a complete response.

Adalimumab improved folliculitis decalvans in most patients.

Belimumab may cause hair loss in lupus patients.

Tildrakizumab significantly improved recalcitrant lichen planopilaris and frontal fibrosing alopecia.

Ustekinumab significantly improved psoriasis, vitiligo, and alopecia areata in a patient.

Real-life dosing of biologics for plaque psoriasis often deviates from recommended guidelines, especially for high-need patients.

Anti-CD19 therapy may help treat SLE and NMOSD.

Ustekinumab successfully treated a man's resistant skin condition when other treatments failed.

Pediatric pemphigus is often diagnosed late, but rituximab helps control it long-term.

Long-term Imiquimod treatment causes initial skin inflammation that lessens over time, and topical corticosteroids reduce this inflammation and cytokines in a mouse model of psoriasis.

Treatment with biologic agents can significantly improve psoriasis symptoms, and blood biomarkers could potentially predict individual patient's response to treatment.

A woman with bullous pemphigoid had an allergic reaction to azathioprine, but got better with alternative treatments.

Ustekinumab effectively treated psoriasis and ulcerative colitis in a teen after infliximab caused complications.

IL-12/23 inhibitors are more effective and have fewer common side effects than anti-TNF alpha for treating psoriasis.

Early use of infliximab in severe pediatric Crohn's disease can lead to significant improvement and remission.

Infliximab improved skin and bowel symptoms in Crohn's disease but caused side effects and the disease returned after stopping treatment.

Tocilizumab treatment was associated with significant hair regrowth in one patient and temporary hair loss followed by regrowth in another.

Dupilumab improves skin microbiome balance in atopic dermatitis patients.

Anti-IL-12/IL-23 antibody therapy effectively treats psoriasiform skin lesions in IBD patients.

Adalimumab significantly improved symptoms and quality of life in two patients with Hidradenitis Suppurativa.

A patient with multiple sclerosis developed skin reactions after Daclizumab treatment, requiring more data on the drug's effects.